AbbVie and Roche Seek FDA Approval for Venclexta-Gazyva Combination in First-line CLL Treatment
Key Insights
AbbVie (search) and Roche have filed for FDA approval of Venclexta plus Gazyva combination therapy for previously untreated chronic lymphocytic leukemia (search) patients with comorbidities.
The Phase 3 CLL14 (search) trial demonstrated significant improvement in progression-free survival with the Venclexta-Gazyva combination compared to standard chemotherapy-based treatment.
The FDA is reviewing the application under its real-time oncology review program, with potential approval expected by year-end, targeting approximately 20,000 new patients in the US.
AbbVie (search) and Roche have submitted a regulatory filing to the US Food and Drug Administration (FDA) seeking approval for their BCL-2 inhibitor Venclexta (venetoclax) in combination with anti-CD20 drug Gazyva (obinutuzumab) for previously untreated chronic lymphocytic leukemia (search) (CLL (search)) patients with coexisting medical conditions.
The application, which has received breakthrough therapy designation from the FDA, is supported by compelling data from the phase 3 CLL14 (search) trial. Results showed that the Venclexta-Gazyva combination significantly reduced the risk of disease progression or death compared to the current standard of Gazyva plus chemotherapy.
Clinical Significance and Market Impact
The potential approval would mark a significant advancement in first-line CLL (search) treatment, offering patients a chemotherapy-free option with a fixed-duration regimen. This differentiates it from existing treatments like the Imbruvica-Gazyva combination, which requires indefinite administration.
"Many newly-diagnosed CLL (search) patients are ineligible for intensive chemotherapy," notes Dr. Sandra Horning, Roche's chief medical officer. "We are working closely with the agency to bring this new option to people with previously untreated chronic lymphocytic leukemia (search) as quickly as possible."
Regulatory Review and Commercial Prospects
The FDA is evaluating the application under its real-time oncology review (RTOR) pilot program, which allows the agency to begin assessing clinical data as soon as trial results become available. This expedited review process could lead to approval before the end of the year.
The expansion into the first-line setting would open access to approximately 20,000 additional potential patients in the US alone. This represents a significant commercial opportunity for both companies, building on Venclexta's existing approvals in relapsed/refractory CLL (search) and acute myeloid leukemia.
Growing Treatment Portfolio
Venclexta has shown promising growth, with worldwide sales reaching $344 million in the previous year, more than double its prior year performance. AbbVie (search) projects sales to exceed $725 million this year.
The companies are further exploring Venclexta's potential through various combination studies, including:
- Combination with Imbruvica as another chemotherapy-free option
- Triple therapy with Imbruvica and Gazyva
- Studies in multiple myeloma, non-Hodgkin lymphoma, and myelodysplastic syndrome
The collaboration between AbbVie (search) and Roche involves co-marketing Venclexta in the US, while AbbVie markets it independently as Venclyxto in other regions.